AKT1 and cancer: With superior efficacy in cancer treatment, doxycycline exerts powerful inhibitory effects on the PAR1/Akt/NF-κB/miR-17/E-cadherin pathway, which reverses aggressive phenotype and represses the motility of cancerous cells [170].